Anthony Mazzarese, PharmD, MSPBA

Drug development and innovation could render the current specialty pharmacy model obsolete in 20 years.

Exclusive, limited, and open networks each have pros and cons that must be weighed heavily.

Challenges to specialty pharmacy profits will need to be overcome for smaller pharmacies to survive.